Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to -$14.2 million.

  • Fulcrum Therapeutics' Cash from Operations rose 2559.77% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.0 million, marking a year-over-year decrease of 59678.47%. This contributed to the annual value of -$2.2 million for FY2024, which is 9756.17% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Cash from Operations stood at -$14.2 million for Q3 2025, which was up 2559.77% from -$13.8 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Cash from Operations' 5-year high stood at $58.9 million during Q2 2024, with a 5-year trough of -$27.9 million in Q3 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$20.8 million (2023), whereas its average is -$16.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 40117.67% in 2021, then soared by 38337.26% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Cash from Operations (Quarter) stood at -$21.9 million in 2021, then grew by 9.89% to -$19.7 million in 2022, then dropped by 17.58% to -$23.2 million in 2023, then increased by 27.62% to -$16.8 million in 2024, then increased by 15.34% to -$14.2 million in 2025.
  • Its last three reported values are -$14.2 million in Q3 2025, -$13.8 million for Q2 2025, and -$15.3 million during Q1 2025.